Restricting HIV the SAMHD1 way: Through nucleotide starvation

Nature Reviews Microbiology

Volumn 10, Issue 10, 2012, Pages 675-680

  Ayinde, Diana ^a   Casartelli, Nicoletta ^a   Schwartz, Olivier ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; INTERFERON; NUCLEOTIDE; SAMHD 1 PROTEIN; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; VIRUS DNA;

ARTICLE; BINDING SITE; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DNA REPAIR; DNA REPLICATION; DNA SYNTHESIS; DOUBLE STRANDED DNA BREAK; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2; HYDROLYSIS; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN NUCLEIC ACID INTERACTION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; SIGNAL TRANSDUCTION; SINGLE STRANDED DNA BREAK; TRANSCRIPTION REGULATION; VIRUS ISOLATION; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; DEOXYRIBONUCLEOTIDES; GENE SILENCING; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; MICE; MONOMERIC GTP-BINDING PROTEINS; NERVOUS SYSTEM MALFORMATIONS; VIRAL REGULATORY AND ACCESSORY PROTEINS; VIRUS REPLICATION;

EID: 84867857245     PISSN: 17401526     EISSN: 17401534     Source Type: Journal    
DOI: 10.1038/nrmicro2862     Document Type: Article

References (92)

1. Sheehy, A. M., Gaddis, N. C., Choi, J. D. & Malim, M. H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646-650 (2002).
2. Zhang, H. et al. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424, 94-98 (2003). (Pubitemid 36834848)
3. Mangeat, B. et al. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424, 99-103 (2003). (Pubitemid 36834849)
4. Lecossier, D., Bouchonnet, F., Clavel, F. & Hance, A. J. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300, 1112 (2003). (Pubitemid 36583087)
5. Stremlau, M. et al. The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys. Nature 427, 848-853 (2004). (Pubitemid 38297747)
6. Stremlau, M. et al. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5α restriction factor. Proc. Natl Acad. Sci. USA 103, 5514-5519 (2006).
7. Yap, M. W., Nisole, S., Lynch, C. & Stoye, J. P. Trim5α protein restricts both HIV-1 and murine leukemia virus. Proc. Natl Acad. Sci. USA 101, 10786-10791 (2004). (Pubitemid 38955820)
8. Van Damme, N. et al. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3, 245-252 (2008). (Pubitemid 351494713)
9. Miyagi, E., Andrew, A. J., Kao, S. & Strebel, K. Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proc. Natl Acad. Sci. USA 106, 2868-2873 (2009).
10. Neil, S. J., Zang, T. & Bieniasz, P. D. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451, 425-430 (2008). (Pubitemid 351158893)
11. Schoggins, J. W. et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472, 481-485 (2011).
12. Yu, X. et al. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302, 1056-1060 (2003). (Pubitemid 37386201)
13. Sheehy, A. M., Gaddis, N. C. & Malim, M. H. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nature Med. 9, 1404-1407 (2003). (Pubitemid 37466190)
14. Goffinet, C. et al. HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe 5, 285-297 (2009).
15. Mangeat, B. et al. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog. 5, e1000574 (2009).
16. Bergamaschi, A. et al. The human immunodeficiency virus type 2 Vpx protein usurps the CUL4A-DDB1DCAF1 ubiquitin ligase to overcome a postentry block in macrophage infection. J. Virol. 83, 4854-4860 (2009).
17. Goujon, C. et al. SIVSM/HIV-2 Vpx proteins promote retroviral escape from a proteasome-dependent restriction pathway present in human dendritic cells. Retrovirology 4, 2 (2007).
18. Kaushik, R., Zhu, X., Stranska, R., Wu, Y. & Stevenson, M. A cellular restriction dictates the permissivity of nondividing monocytes/macrophages to lentivirus and gammaretrovirus infection. Cell Host Microbe 6, 68-80 (2009).
19. Schule, S. et al. Restriction of HIV-1 replication in monocytes is abolished by Vpx of SIVsmmPBj. PLoS ONE 4, e7098 (2009).
20. Sharova, N. et al. Primate lentiviral Vpx commandeers DDB1 to counteract a macrophage restriction. PLoS Pathog. 4, e1000057 (2008).
21. Srivastava, S. et al. Lentiviral Vpx accessory factor targets VprBP/DCAF1 substrate adaptor for cullin 4 E3 ubiquitin ligase to enable macrophage infection. PLoS Pathog. 4, e1000059 (2008).
22. Hrecka, K. et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 474, 658-661 (2011).
23. Laguette, N. et al. SAMHD1 is the dendritic-and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 474, 654-657 (2011).
24. Belshan, M. et al. Vpx is critical for SIVmne infection of pigtail macaques. Retrovirology 9, 32 (2012).
25. Gibbs, J. S. et al. Progression to AIDS in the absence of a gene for vpr or vpx. J. Virol. 69, 2378-2383 (1995).
26. Hirsch, V. M. et al. Vpx is required for dissemination and pathogenesis of SIVSM PBj: evidence of macrophage-dependent viral amplification. Nature Med. 4, 1401-1408 (1998). (Pubitemid 28553463)
27. Ayinde, D., Maudet, C., Transy, C. & Margottin-Goguet, F. Limelight on two HIV/SIV accessory proteins in macrophage infection: is Vpx overshadowing Vpr? Retrovirology 7, 35 (2010).
28. Aravind, L. & Koonin, E. V. The HD domain defines a new superfamily of metal-dependent phosphohydrolases. Trends Biochem. Sci. 23, 469-472 (1998). (Pubitemid 29002909)
29. Qiao, F. & Bowie, J. U. The many faces of SAM. Sci. STKE 2005, re7 (2005).
30. Lahouassa, H. et al. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nature Immunol. 13, 223-228 (2012).
31. Ahn, J. et al. HIV/simian immunodeficiency virus (SIV) accessory virulence factor Vpx loads the host cell restriction factor SAMHD1 onto the E3 ubiquitin ligase complex CRL4DCAF1. J. Biol. Chem. 287, 12550-12558 (2012).
32. Pancio, H. A., Vander Heyden, N. & Ratner, L. The C-terminal proline-rich tail of human immunodeficiency virus type 2 Vpx is necessary for nuclear localization of the viral preintegration complex in nondividing cells. J. Virol. 74, 6162-6167 (2000). (Pubitemid 30412988)
33. Singhal, P. K., Rajendra Kumar, P., Subba Rao, M. R. & Mahalingam, S. Nuclear export of simian immunodeficiency virus Vpx protein. J. Virol. 80, 12271-12282 (2006). (Pubitemid 44904377)
34. Brandariz-Nunez, A. et al. Role of SAMHD1 nuclear localization in restriction of HIV-1 and SIVmac. Retrovirology 9, 49 (2012).
35. Rice, G. I. et al. Mutations involved in Aicardi-Goutières syndrome implicate SAMHD1 as regulator of the innate immune response. Nature Genet. 41, 829-832 (2009).
36. Li, N., Zhang, W. & Cao, X. Identification of human homologue of mouse IFN-γ induced protein from human dendritic cells. Immunol. Lett. 74, 221-224 (2000).
37. Berger, A. et al. SAMHD1-deficient CD14+ cells from individuals with Aicardi-Goutières syndrome are highly susceptible to HIV-1 infection. PLoS Pathog. 7, e1002425 (2011).
38. Li, S., Wang, L., Berman, M., Kong, Y. Y. & Dorf, M. E. Mapping a dynamic innate immunity protein interaction network regulating type I interferon production. Immunity 35, 426-440 (2011).
39. Gramberg, T., Sunseri, N. & Landau, N. R. Evidence for an activation domain at the amino terminus of simian immunodeficiency virus Vpx. J. Virol. 84, 1387-1396 (2010).
40. Prehaud, C., Megret, F., Lafage, M. & Lafon, M. Virus infection switches TLR-3-positive human neurons to become strong producers of beta interferon. J. Virol. 79, 12893-12904 (2005). (Pubitemid 41433208)
41. Powell, R. D., Holland, P. J., Hollis, T. & Perrino, F. W. Aicardi-Goutières syndrome gene and HIV-1 restriction factor SAMHD1 is a dGTP-regulated deoxynucleotide triphosphohydrolase. J. Biol. Chem. 286, 43596-43600 (2011).
42. Goldstone, D. C. et al. HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature 480, 379-382 (2011).
43. Kim, B., Nguyen, L. A., Daddacha, W. & Hollenbaugh, J. A. Tight interplay among SAMHD1 protein level, cellular dNTP levels and HIV-1 proviral, DNA synthesis kinetics in human primary monocyte-derived macrophages. J. Biol. Chem. 287, 21570-21574 (2012).
44. Diamond, T. L. et al. Macrophage tropism of HIV-1 depends on efficient cellular dNTP utilization by reverse transcriptase. J. Biol. Chem. 279, 51545-51553 (2004). (Pubitemid 40017904)
45. Kennedy, E. M. et al. Ribonucleoside triphosphates as substrate of human immunodeficiency virus type 1 reverse transcriptase in human macrophages. J. Biol. Chem. 285, 39380-39391 (2010).
46. Gao, W. Y., Cara, A., Gallo, R. C. & Lori, F. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc. Natl Acad. Sci. USA 90, 8925-8928 (1993). (Pubitemid 23306423)
47. Hofer, A., Crona, M., Logan, D. T. & Sjoberg, B. M. DNA building blocks: keeping control of manufacture. Crit. Rev. Biochem. Mol. Biol. 47, 50-63 (2012).
48. Mathews, C. K. DNA precursor metabolism and genomic stability. FASEB J. 20, 1300-1314 (2006). (Pubitemid 44943838)
49. Niida, H., Shimada, M., Murakami, H. & Nakanishi, M. Mechanisms of dNTP supply that play an essential role in maintaining genome integrity in eukaryotic cells. Cancer Sci. 101, 2505-2509 (2010).
50. Rampazzo, C. et al. Regulation by degradation, a cellular defense against deoxyribonucleotide pool imbalances. Mutat. Res. 703, 2-10 (2010).
51. Clouser, C. L., Patterson, S. E. & Mansky, L. M. Exploiting drug repositioning for discovery of a novel HIV combination therapy. J. Virol. 84, 9301-9309 (2010).
52. Kootstra, N. A., Zwart, B. M. & Schuitemaker, H. Diminished human immunodeficiency virus type 1 reverse transcription and nuclear transport in primary macrophages arrested in early G1 phase of the cell cycle. J. Virol. 74, 1712-1717 (2000). (Pubitemid 30434027)
53. Lori, F. et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 266, 801-805 (1994). (Pubitemid 24359288)
54. Tanaka, H. et al. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404, 42-49 (2000). (Pubitemid 30143125)
55. Chabes, A. & Thelander, L. Controlled protein degradation regulates ribonucleotide reductase activity in proliferating mammalian cells during the normal cell cycle and in response to DNA damage and replication blocks. J. Biol. Chem. 275, 17747-17753 (2000). (Pubitemid 30430824)
56. O'Brien, W. A. et al. Kinetics of human immunodeficiency virus type 1 reverse transcription in blood mononuclear phagocytes are slowed by limitations of nucleotide precursors. J. Virol. 68, 1258-1263 (1994). (Pubitemid 24022239)
57. Korin, Y. D. & Zack, J. A. Nonproductive human immunodeficiency virus type 1 infection in nucleoside-treated G0 lymphocytes. J. Virol. 73, 6526-6532 (1999). (Pubitemid 29327833)
58. Ravot, E., Comolli, G., Lori, F. & Lisziewicz, J. High efficiency lentiviral gene delivery in non-dividing cells by deoxynucleoside treatment. J. Gene Med. 4, 161-169 (2002). (Pubitemid 40277166)
59. Vatakis, D. N., Nixon, C. C. & Zack, J. A. Quiescent T cells and HIV: an unresolved relationship. Immunol. Res. 48, 110-121 (2010).
60. Plesa, G. et al. Addition of deoxynucleosides enhances human immunodeficiency virus type 1 integration and 2LTR formation in resting CD4+ T cells. J. Virol. 81, 13938-13942 (2007). (Pubitemid 350247888)
61. Skasko, M. et al. Mechanistic differences in RNA-dependent DNA polymerization and fidelity between murine leukemia virus and HIV-1 reverse transcriptases. J. Biol. Chem. 280, 12190-12200 (2005).
62. Jamburuthugoda, V. K., Chugh, P. & Kim, B. Modification of human immunodeficiency virus type 1 reverse transcriptase to target cells with elevated cellular dNTP concentrations. J. Biol. Chem. 281, 13388-13395 (2006). (Pubitemid 43855250)
63. Pontarin, G. et al. p53R2-dependent ribonucleotide reduction provides deoxyribonucleotides in quiescent human fibroblasts in the absence of induced DNA damage. J. Biol. Chem. 282, 16820-16828 (2007). (Pubitemid 47093192)
64. Cohen, D., Adamovich, Y., Reuven, N. & Shaul, Y. Hepatitis B virus activates deoxynucleotide synthesis in nondividing hepatocytes by targeting the R2 gene. Hepatology 51, 1538-1546 (2010).
65. Cameron, J. M. et al. Ribonucleotide reductase encoded by herpes simplex virus is a determinant of the pathogenicity of the virus in mice and a valid antiviral target. J. Gen. Virol. 69, 2607-2612 (1988).
66. Jacobson, J. G. et al. A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells. Virology 173, 276-283 (1989). (Pubitemid 19268271)
67. Guittet, O. et al. Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells. J. Biol. Chem. 276, 40647-40651 (2001).
68. Mock, D. J. et al. Leishmania induces survival, proliferation and elevated cellular dNTP levels in human monocytes promoting acceleration of HIV co-infection. PLoS Pathog. 8, e1002635 (2012).
69. de Silva, T. I., Cotten, M. & Rowland-Jones, S. L. HIV-2: the forgotten AIDS virus. Trends Microbiol. 16, 588-595 (2008).
70. Duvall, M. G. et al. Dendritic cells are less susceptible to human immunodeficiency virus type 2 (HIV-2) infection than to HIV-1 infection. J. Virol. 81, 13486-13498 (2007). (Pubitemid 350247843)
71. Manel, N. et al. A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells. Nature 467, 214-217 (2010).
72. Nobile, C. et al. Covert human immunodeficiency virus replication in dendritic cells and in DC-SIGN-expressing cells promotes long-term transmission to lymphocytes. J. Virol. 79, 5386-5399 (2005). (Pubitemid 40548207)
73. Laguette, N. et al. Evolutionary and functional analyses of the interaction between the myeloid restriction factor SAMHD1 and the lentiviral Vpx protein. Cell Host Microbe 11, 205-217 (2012).
74. Lim, E. S. et al. The ability of primate lentiviruses to degrade the monocyte restriction factor SAMHD1 preceded the birth of the viral accessory protein Vpx. Cell Host Microbe 11, 194-204 (2012).
75. Zhang, C., de Silva, S., Wang, J. H. & Wu, L. Co-evolution of primate SAMHD1 and lentivirus Vpx leads to the loss of the vpx gene in HIV-1 ancestor. PLoS ONE 7, e37477 (2012).
76. Sharp, P. M., Bailes, E., Stevenson, M., Emerman, M. & Hahn, B. H. Gene acquisition in HIV and SIV. Nature 383, 586-587 (1996).
77. Tristem, M., Marshall, C., Karpas, A., Petrik, J. & Hill, F. Origin of vpx in lentiviruses. Nature 347, 341-342 (1990). (Pubitemid 20332301)
78. Brasey, A. et al. The leader of human immunodeficiency virus type 1 genomic RNA harbors an internal ribosome entry segment that is active during the G2/M phase of the cell cycle. J. Virol. 77, 3939-3949 (2003). (Pubitemid 36350935)
79. Fletcher, T. M. 3rd et al. Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2/SIVSM. EMBO J. 15, 6155-6165 (1996).
80. Goh, W. C. et al. HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nature Med. 4, 65-71 (1998). (Pubitemid 28133081)
81. Lepelley, A. et al. Innate sensing of HIV-infected cells. PLoS Pathog. 7, e1001284 (2011).
82. Beignon, A. S. et al. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J. Clin. Invest. 115, 3265-3275 (2005).
83. Crow, Y. J. & Rehwinkel, J. Aicardi-Goutières syndrome and related phenotypes: linking nucleic acid metabolism with autoimmunity. Hum. Mol. Genet. 18, R130-R136 (2009).
84. Prinz, M. & Knobeloch, K. P. Type I interferons as ambiguous modulators of chronic inflammation in the central nervous system. Front. Immunol. 3, 67 (2012).
85. Nagpal, K. et al. A TIR domain variant of MyD88 adapter-like (Mal)/TIRAP results in loss of MyD88 binding and reduced TLR2/TLR4 signaling. J. Biol. Chem. 284, 25742-25748 (2009).
86. Aicardi, J. & Goutières, F. A progressive familial encephalopathy in infancy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis. Ann. Neurol. 15, 49-54 (1984). (Pubitemid 14224219)
87. Crow, Y. J. et al. Mutations in the gene encoding the 3Ŷ-5' DNA exonuclease TREX1 cause Aicardi-Goutières syndrome at the AGS1 locus. Nature Genet. 38, 917-920 (2006). (Pubitemid 44141660)
88. Crow, Y. J. et al. Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutières syndrome and mimic congenital viral brain infection. Nature Genet. 38, 910-916 (2006). (Pubitemid 44141659)
89. Yan, N., Regalado-Magdos, A. D., Stiggelbout, B., Lee-Kirsch, M. A. & Lieberman, J. The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nature Immunol. 11, 1005-1013 (2010).
90. Hiller, B. et al. Mammalian RNase H2 removes ribonucleotides from DNA to maintain genome integrity. J. Exp. Med. 209, 1419-1426 (2012).
91. Lazzaro, F. et al. RNase H and postreplication repair protect cells from ribonucleotides incorporated in DNA. Mol. Cell 45, 99-110 (2012).
92. Genovesio, A. et al. Automated genome-wide visual profiling of cellular proteins involved in HIV infection. J. Biomol. Screen 16, 945-958 (2011).